Who is sponsoring NCT03870204?

NCT03870204 is sponsored by Ina-Respond.

What drugs are being tested in NCT03870204?

Interventions in NCT03870204: POC-CCA rapid urine test.

What condition does NCT03870204 study?

NCT03870204 studies Aged ≥2 Years in Schistosomiasis Affected Areas.

Is NCT03870204 still recruiting?

NCT03870204 is currently completed. Last updated 2 November 2021.

Last reviewed 2021-11-02 · How we verify

NCT03870204: SchisCCA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Validation of POC-CCA Rapid Urine Test for Qualitative Detection of Schistosoma Japonicum

Completed Last updated 2 November 2021

What this trial tests

trial testing POC-CCA rapid urine test in Aged ≥2 Years in Schistosomiasis Affected Areas in 186 participants. Completed in 2 July 2020.

Timeline

4 September 2019

Primary endpoint
2 July 2020

2 July 2020

Quick facts

Lead sponsor	Ina-Respond
Status	Completed
Study type	OBSERVATIONAL
Enrollment	186
Start date	4 September 2019
Primary completion	2 July 2020
Estimated completion	2 July 2020
Sites	1 location across Indonesia

Drugs / interventions tested

POC-CCA rapid urine test

Conditions studied

Aged ≥2 Years in Schistosomiasis Affected Areas — all drugs for Aged ≥2 Years in Schistosomiasis Affected Areas →

Sponsor

Ina-Respond — full company profile →

Who can join

2 and older, any sex, with Aged ≥2 Years in Schistosomiasis Affected Areas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a longitudinal cohort study that will be coordinated with the 2019 schistosomiasis stool survey in Napu. The study will use the stool survey results as entry criteria to identify subjects to become the index cases. Contact investigation will be conducted to the index cases during home visit (Visit 1). The index cases and their contacts meeting the study's eligibility criteria will be recruited. For Visit 1, they will be tested for schistosomiasis by on the spot POC-CCA, stool samples will be tested for KK at Donggala R\&D Center Laboratory and urinary tract infection (UTI) by urine dipsticks, stool samples will be tested for schistosomiasis and soil transmitted helminths (STH) by KK at Donggala R\&D Center Laboratory and by molecular assay (Taqman qPCR) at the INA-RESPOND Reference Laboratory, while dried blood spots samples will be tested for schistosome antibodies by ELISA at the INA-RESPOND Reference Laboratory. The study KK and/or POC-CCA will be used to determine their schistosomiasis status. Those with positive schistosomiasis status by KK and/or POC-CCA will continue follow up to Visit 2 and 3.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia.
Karyana M, Kosasih H, Neal AT, Lau CY. · · 2021 · cited 3× · PMID 34326986 · DOI 10.7189/jogh.11.03087

Verify or expand the search:

Other Ina-Respond trials

Trials by the same sponsor.

NCT04339179 — Observational Research on Infectious Disease Outbreaks and Difficult Cases of Unidentified Etiology in Indonesia · completed
NCT04535856 — Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients · Phase 1 · completed
NCT04613271 — Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia · Phase 3 · completed
NCT04331782 — Integration of Mental Health in HIV Clinic to Increase the Success of ARV Treatment in PLWHA in Hospitals · completed
NCT03663920 — HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03870204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ina-Respond
Last refreshed: 2 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03870204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing